{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:42Z","timestamp":1793467602514,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In September 2023, the US Food and Drug Administration approved momelotinib for the treatment of myelofibrosis (MF) with anemia, marking the fourth US regulatory approval of a Janus kinase inhibitor for MF. A positive opinion from the European Medicines Agency followed in November 2023. Momelotinib\u2019s ability to address splenomegaly, symptoms, and anemia, including in patients with thrombocytopenia (with platelet counts of \u226525\u00a0\u00d7 109\/L), the ease of switching from ruxolitinib, and good tolerability uniquely position it to substantially impact the MF treatment landscape.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023719","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T13:06:54Z","timestamp":1720012014000},"page":"708-713","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Momelotinib for the treatment of myelofibrosis"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2024081515210297400_bib1","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2024081515210297400_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in\u00a0rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024081515210297400_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"18","key":"2024081515210297400_bib4","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024081515210297400_bib5","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/leu.2017.330","article-title":"Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis","volume":"32","author":"Pardanani","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2024081515210297400_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2024081515210297400_bib7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2024081515210297400_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3324\/haematol.2023.283106","article-title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","volume":"109","author":"Mesa","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2024081515210297400_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26778","article-title":"Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2024081515210297400_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/leu.2014.306","article-title":"Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2024081515210297400_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.13262","article-title":"Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis","volume":"169","author":"Abdelrahman","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2024081515210297400_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: a 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024081515210297400_bib13","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"issue":"34","key":"2024081515210297400_bib14","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024081515210297400_bib15","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2024081515210297400_bib16","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"2024081515210297400_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","article-title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","volume":"63","author":"Mesa","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024081515210297400_bib18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2024081515210297400_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A\u00a0pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2024081515210297400_bib20","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"2024081515210297400_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jval.2024.01.014","article-title":"Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies","volume":"27","author":"Hudgens","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"2024081515210297400_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jha2.854","article-title":"Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis","volume":"5","author":"Oh","year":"2024","journal-title":"EJHaem"},{"issue":"11","key":"2024081515210297400_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10373","key":"2024081515210297400_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"2024081515210297400_bib25","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"2024081515210297400_bib26","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/cancers15133331","article-title":"Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments","volume":"15","author":"Chifotides","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2024081515210297400_bib27","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2024081515210297400_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/fon-2023-0964","article-title":"Anemia-related response end points in myelofibrosis clinical trials: current trends and needs for renewed consensus","volume":"20","author":"Klenche","year":"2024","journal-title":"Future Oncol"},{"issue":"3","key":"2024081515210297400_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"2024081515210297400_bib30","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1097\/HS9.0000000000000963","article-title":"Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials","volume":"7","author":"Kiladjian","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024081515210297400_bib31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind phase 3 study [abstract]","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"key":"2024081515210297400_bib32","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","author":"Gerds","year":"31  2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024081515210297400_bib33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2023-180164","article-title":"Phase 1\/2 study of TP-3654, a selective PIM1 kinase inhibitor: preliminary data showed clinical activity and cytokine reductions in relapsed\/refractory myelofibrosis patients [abstract]","volume":"142","author":"Rein","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/7\/708\/2237730\/blood_bld-2023-023719-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/7\/708\/2237730\/blood_bld-2023-023719-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:21:30Z","timestamp":1723735290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/7\/708\/516831\/Momelotinib-for-the-treatment-of-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023719","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}